2100.HEALTH
// THE LONGEVITY TERMINAL · EDITION

The frontier of aging reversal — every clinic, every treatment, every trial. Benchmarked.

2100 is the independent terminal for longevity medicine: what's actually available today, which clinics deliver it, what it costs, and how strong the evidence really is — from FDA-approved protocols to the reprogramming trials rewriting the field next. When you find something worth pursuing, we get you in the door.

Browse the terminal ↓

Confidential concierge intake. A 2100 operator reviews your goals and routes you to the right clinic personally — usually within 48 hours. Free; the clinic compensates us only if you proceed, never you.

// What this is

One table for the entire field

Aging-reversal medicine is scattered across private clinics, off-label scripts, and early trials with no public map. 2100 puts every credible option in one place — what it is, where to get it, what it costs, and an honest evidence rating, from large RCTs down to single-trial speculation.

// Who it's for

People who intend to be first in line

You can afford the frontier. What you're missing is a clear map and a way in that isn't a cold email to a clinic that never replies. 2100 is the research desk and the introduction — built for serious buyers, not tire-kickers.

// Start here

How intake works

  1. Tell us your goals, budget, and timeline — two minutes, confidential.
  2. A 2100 operator shortlists the right clinics and routes you personally.
  3. You get a real intake, not a contact form. Free — the clinic pays us.
Frontier Feed
PHASE 1Life Biosciences ER-100 — first-ever partial epigenetic reprogramming in humans, FDA-cleared Jan 2026 PHASE 1Retro Biosciences RTR242 — first-in-human dose Adelaide Dec 2025, AI-designed Yamanaka variants CAPITALAltos Labs $3B preclinical, Sentinel Cell program 2026 PHASE 2Intervene Immune TRIIM-X enrolling — 2.5yr biological age reversal in original 9-man trial SIGNALBuck Institute 2025: TPE+IVIG cut biological age 2.61 years on multi-omic clocks REGFDA Category 2 on BPC-157 — most peptide compounding restricted 2024-2025 RXSELECT trial: semaglutide cut cardiovascular events 20% in non-diabetics FRONTIERStem Cell Institute Panama — 'Golden Cells' umbilical cord MSCs, no FDA jurisdiction
filter: clear

Named clinics. Where the protocols actually run. The further down the table, the further outside FDA jurisdiction — and the more recently the molecule reached the patient. Click any row for services, treatments offered, and pricing tiers.

Clinic Country Focus Offerings Tier

Off-label prescriptions, OTC supplements, and procedures running today. Evidence ranges from large RCT (GLP-1) to single-trial speculation (HBOT, exosomes). Read the rating before reading the headline.

Sym Asset Status Evidence Hallmark Price
●●●●● Strong human RCTs
●●●● Early human data
●●●●● Animal + observational
●●●●● Preclinical / mechanistic
●●●● Speculative

The frontier. Five categories, fourteen named programs, $3B+ in known capital. First human reprogramming results expected 2026-2027. Where today's "speculative" becomes tomorrow's standard of care.

Sym Program Phase Lead Sponsor First results

Measure first or you're flying blind. Epigenetic clocks compress 20-year mortality studies into a 6-month feedback loop — the most important development in this guide.

Test Best option Cost Frequency